195 related articles for article (PubMed ID: 36048862)
1. Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate.
Kolterud Å; Välimäki N; Kuisma H; Patomo J; Ilves ST; Mäkinen N; Kaukomaa J; Palin K; Kaasinen E; Karhu A; Pasanen A; Bützow R; Heikinheimo O; Kopp Kallner H; Aaltonen LA
Hum Mol Genet; 2023 Mar; 32(7):1063-1071. PubMed ID: 36048862
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
3. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
5. A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.
Ng SSM; Jorge S; Malik M; Britten J; Su SC; Armstrong CR; Brennan JT; Chang S; Baig KM; Driggers PH; Segars JH
J Clin Endocrinol Metab; 2019 Mar; 104(3):970-980. PubMed ID: 30239831
[TBL] [Abstract][Full Text] [Related]
6. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
7. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
8. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
10. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
11. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
13. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
14. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.
Moravek MB; Bulun SE
Curr Opin Obstet Gynecol; 2015 Aug; 27(4):276-83. PubMed ID: 26107781
[TBL] [Abstract][Full Text] [Related]
15. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
16. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
18. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
Small B; Millard CEF; Kisanga EP; Burman A; Anam A; Flannery C; Al-Hendy A; Whirledge S
J Clin Endocrinol Metab; 2020 Mar; 105(3):716-34. PubMed ID: 31665442
[TBL] [Abstract][Full Text] [Related]
19. Ulipristal acetate: in uterine fibroids.
Croxtall JD
Drugs; 2012 May; 72(8):1075-85. PubMed ID: 22568731
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]